Skip to main content
Premium Trial:

Request an Annual Quote

BioMerieux to Incorporate Cepheid s Platform in Molecular Diagnostics

NEW YORK, Jan. 6 (GenomeWeb News) - BioMerieux of Marcy-l'Etoile, France, plans to develop molecular diagnostics systems using Cepheid's platform technologies, Sunnyvale, Calif.-based Cepheid said today.

 

The testing units will combine BioMerieux's NASBA (Nucleic Acid Sequence-Based Amplification) technology and Cepheid's Smart Cycler and GeneXpert platforms.

 

BioMerieux will pay Cepheid a total of $15 million in upfront and milestone payments, including a $2 million option payment received in October 2003. Cepheid will also receive payments from product purchases and royalties. 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.